Risankizumab (SKYRIZI) ELISA Assay Kit


The Risankizumab (SKIRIZI) ELISA Assay Kit is used as an analytical tool for quantitative determination of Risankizumab in human serum and plasma. The Risankizumab (SKIRIZI) ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

Risankizumab (SKYRIZI) ELISA Assay Kit

The Risankizumab (SKYRIZI) ELISA Assay Kit is For Research Use Only

Size: 1 x 96 wells
Calibrator Range: 10 – 640 ng/mLL
Sample Size: 100 uL
Sample Type: Serum and Plasma
Incubation Time: 2 hours 30 minutes

Assay Background

Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Risankizumab was approved by the U.S. FDA for treatment of moderate-to-severe plaque psoriasis in April 2019, and in vitro, has been more potent in inhibiting IL-23 signalling than other drugs performing in the same IL-23 complex.

Assay Principle

IL-23A Protein is pre-coated onto microwells. Samples and standards are pipetted into microwells. Risankizumab present in the sample is bound by the protein. Then, an Anti-Human IgG conjugated to HRP is pipetted and incubated. After washing microwells, in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Risankizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Related Products:

Etanercept ELISA Assay Kit
Adalimumab ELISA Assay Kit
Golimumab ELISA Assay Kit
Infliximab ELISA Assay Kit


Product Manual

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations